INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)

ATTY. DOCKET NO.	SERIAL NO.
114232.104	09/518,081
APPLICANT: Leland SHAPIRO	
FILING DATE: March 3, 2000	GROUP: 1646

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/W.M/	AA	4,021,472	5/3/77	Fuji et al			
	AB	4,051,842	10/4/977	Hazel et al.			
	AC	4,140,122	2/20/79	Kuhl et al.			
	AD	4,224,342	9/23/80	Fuji et al			
	AE	4,283,418	8/11/81	Fuji et al			
	AF	4,310,533	1/12/82	Uegai et al			
	AG	4,383,529	5/17/83	Webster			
	AH	4,629,567	12/16/86	Bollen et al.			
	AI	4,668,504	5/26/87	Kahan et al.			
	AJ	4,711,848	12/8/87	Insley et al.			
	AK	4,713,224	12/15/87	Tamhankar et al.			
	AL	4,732,973	3/22/88	Barr et al			
	AM	4,760,130	7/26/88	Thompson et al.			
	AN	4,788,603	11/29/88	Fujimura et al.			
	AO	4,829,052	5/9/89	Glover et al.			
	AP	4,839,283	6/13/89	Kawasaki et al			
	AQ	4,843,094	6/27/89	Imaki et al			
	AR	4,889,723	12/26/89	Kim et al			
	AS	4,931,279	6/5/90	Bawa et al.			
	AT	4,963,654	10/16/90	Katunuma			
	AU	5,004,612	4/2/91	Kim et al			
	AV	5,077,428	12/31/91	Imaki et al			
	AW	5,110,602	5/5/92	Kim et al			
	AX	5,157,019	10/23/92	Glover et al.			
	AY	5,175,253	12/29/92	Fallon et al.			
	AZ	5,214,191	5/25/93	Kirschenheuter et al			
	AAA	5,240,956	8/31/93	Kirschenheuter et al			
	AAB	5,247,084	9/21/93	Imaki et al			
/W.M/	AAC	5,281,617	1/25/94	Kirschenheuter et al			

EXAMINER	/William Moore/	DATE CONSIDERED	04/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.M./

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)

ATTY. DOCKET NO.	SERIAL NO.
114232.104	09/518,081
APPLICANT	
Leland SHAPIRO	
FILING DATE	GROUP
March 3, 2000	1646

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AAD	5,314,910	5/24/94	Kirschenheuter et al			
	AAE	5,376,655	12/27/94	Imaki et al			
	AAF	5,399,346	3/21/95	Anderson et al.			
	AAG	5,416,191	5/16/95	Cheronis et al			
	AAH	5,420,110	5/30/95	Miller et al.			
	AAI	5,432,178	7/11/95	Nakai et al			
	AAJ	5,470,970	11/28/95	Saeger et al.			
	AAK	5,476,995	12/19/95	Clark et al			
	AAL	5,478,727	12/26/95	Roizman et al			
	AAM	5,486,470	1/23/96	Darke et al			
	AAN	5,514,653	5/7/96	Perlmutter			
	AAO	5,514,713	5/7/96	Nakai et al			
	AAP	5,529,920	6/25/96	Cole et al.			
	AAQ	5,532,215	7/2/96	Lezdey et al.			
	AAR	5,565,334	10/15/96	Kufe et al			
	AAS	5,593,858	1/14/97	Fleer et al			
	AAT	5,604,201	2/18/97	Thomas et al.			
	AAU	5,610,140	3/11/97	Goodfellow et al			
	AAV	5,610,285	3/11/97	Lebing et al.			
	AAW	5,614,555	3/25/97	Nakai et al			
	AAX	5,616,693	4/1/97	Hwang et al.			
	AAY	5,618,792	4/8/97	Gyorkos et al.			
	AAZ	5,622,984	4/22/97	Nakai et al			
	ABA	5,635,593	6/3/97	Cheronis et al			
	ABB	5,641,670	6/24/97	Treco et al			
	ABC	5,663,416	9/2/97	Kirschenheuter et al			

EXAMINER	/William Moore/	DATE CONSIDERED	04/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.M./

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
	APPLICANT Leland SHAPIRO	
	FILING DATE March 3, 2000	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	ABD	5,665,589	9/9/97	Harris et al			
	ABE	5,700,779	12/23/97	Goodfellow et al			
	ABF	5,710,026	1/20/98	Sprecher			
	ABG	5,712,117	1/27/98	Sprecher			
	ABH	5,747,645	6/6/98	Sprecher			
	AJI	5,750,506	5/12/98	Goodfellow et al			
	ABJ	5,759,548	6/2/98	Bathurst et al.			
	ABK	5,780,009	7/14/98	Karatzas et al			
	ABL	5,798,442	8/25/98	Gallant et al.			
	ABM	5,801,148	9/1/??	Gyorkos et al			
	ABN	5,807,829	9/15/98	Gyorkos et al			
	ABO	5,811,241	9/22/98	Goodfellow et al			
	ABP	5,817,484	10/6/98	Yu et al			
	ABQ	5,834,431	11/10/98	Stewart et al			
	ABR	5,843,900	12/1/98	Cheronis et al			
	ABS	5,849,863	12/15/98	Stewart et al			
	ABT	5,861,299	1/19/99	Archibald et al			
	ABU	5,861,380	1/19/99	Gyorkos et al.			
	ABV	5,863,899	1/26/99	Cheronis et al			
	ABW	5,869,455	2/9/99	Gyorkos et al.			
	ABX	5,874,424	2/23/99	Batchelor et al.			
	ABY	5,891,852	4/6/99	Gyorkos et al			

EXAMINER	/William Moore/	DATE CONSIDERED	04/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.M./

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)

ATTY. DOCKET NO.	SERIAL NO.
114232.104	09/518,061
APPLICANT: Leland SHAPIRO	
FILING DATE: March 3, 2000	GROUP: 1646

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes	Translation No
	BA	WO 98/56821	12/17/98	PCT			Abstr.	
	BB	WO 98/20034	5/14/98	PCT				
	BC	WO 98/23565	6/4/98	PCT				
	BD	WO 98/50342	11/12/98	PCT				
	BE	WO 98/50420	11/12/98	PCT				
	BF	WO 97/21690	6/19/97	PCT				
	BG	WO 97/10231	3/20/97	PCT				
	BH	WO 97/03679	2/6/97	PCT				
	BI	WO 98/22619	5/28/98	PCT				
	BJ	WO 98/22098	5/28/98	PCT				
	BK	WO 97/48706	12/24/97	PCT				
	BL	WO 97/33996	9/18/97	PCT				
	BM	WO 98/46597	10/22/98	PCT				
	BN	WO 97/24339	7/10/97	PCT			Abstr	
	BO	WO 98/21186	5/22/98	PCT				
	BP	WO98/09206	3/5/98	PCT			Abstr	
	BQ	WO95/28422	10/26/95	PCT				
	BR	WO95/34538	12/21/95	PCT				
	BS	WO96/12021	4/25/96	PCT				
	BT	WO96/14067	5/17/96	PCT				
	BU	WO97/09346	3/13/97	PCT				
	BV	WO97/09347	3/13/97	PCT				
	BW	WO97/10222	3/20/97	PCT				
	BX	WO97/31937	9/4/97	PCT				
	BY	WO97/37969	10/16/97	WO			Abstr.	
	BZ	WO97/49679	12/31/97	WO			Abstr.	
	BBA	WO97/45402	12/4/97	WO				
	BBB	WO98/06417	2/29/98	PCT				
	BBC	WO98/49190	11/5/98	PCT				

EXAMINER: /William Moore/ DATE CONSIDERED: 04/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.M./

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
	APPLICANT Leland SHAPIRO	
	FILING DATE March 3, 2000	GROUP 1646

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes	Translation No
	BBD	WO99/41231	8/19/99	WO				
	BBE	WO00/52034	9/8/00					
	BBF	WO99/43308	9/2/99					
	BBG	WO94/07525	4/14/94	WO				

EXAMINER	/William Moore/	DATE CONSIDERED	04/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.M./

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
	APPLICANT Leland SHAPIRO	
	FILING DATE March 3, 2000	GROUP 1646

		OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)
✓	CA	Adelman S.F. et al., "Protease inhibitors suppress fibrinolytic activity of herpesvirus-transformed cells", *J Gen Virol*, **1982**, *60(Pt 1)*:15-24.
✓	CB	Altieri, D.C. *J Leukoc Biol 1995, 58,* ~~120127~~ pp. 120-127
✓	CC	Anderson ED, Thomas L, Hayflick JS, Thomas G., "*Inhibition of HIV-1 gp160-dependent membrane fusion by a furin-directed alpha 1-antitrypsin variant*", J Biol Chem, 268(33):24887-91 (Nov 25, 1993)
	CD	Aoki H, Akaike T, Abe K, Kuroda M, Arai S, Okamura R, Negi A, Maeda H. *Antiviral effect of oryzacystatin, a proteinase inhibitor in rice, against herpes simplex virus type I in vitro and in vivo.* Antimicrob Agents Chemother 1995 Apr;39(4):846-9
✓	CE	Auerswald et al., "K15R M52E) aprotinin is a weak Kunitz-type inhibitor of HIV-1 replication in H9 cells" *Biomed Biochim Acta, **1991**, 50(4-6)*:697-700.
	CF	Auerswald et *al., "Recombinant leech-derived tryptase inhibitor: construction, production, protein chemical characterization and inhibition of HIV-1 replication"*, Biol Chem Hoppe Seyler, 375(10):695-703 (1994)
✓	CG	Avril, et al., "Identification of the U-937 membrane-associated proteinase interacting with the V3 loop of HIV-1 gp120 as cathepsin G", *FEBS Lett*, **1994**, *345(1)*:81-6.
✓	CH	Avril LE, Di Martino-Ferrer M, Barin F, Gauthier F., *"Interaction between a membrane-associated serine proteinase of U-937 monocytes and peptides from the V3 loop of the human immunodeficiency virus type I (HIV-1) gp120 envelope glycoprotein"*, FEBS Lett, 317(1-2):167-72 (Feb 8, 1993)
✓	CI	Banfi G, Pirali A, Locatelli M, Murone M, Bonini PA., *"Tumor-associated trypsin inhibitor in induced and acquired immunodeficiency. Studies on transplanted and HIV-infected patients"*, Scand J Clin Lab Invest, 51 Suppl, 207:55-8 (1991)
	CJ	Beck, K.F. et al. in *J Exp Biol 1999,* 202, ~~64553~~ pp. 645-653
	CK	Bjorck L, Grubb A, Kjellen L. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. J Virol 1990 Feb;64(2):941-3
✓	CL	Bourinbaiar AS, Lee-Huang S., "*Acrosin inhibitor, 4'-(acetamidophenyl 4-guanidinobenzoate, an experimental vaginal contraceptive with anti-HIV activity*", Contraception, 51(5):319-22 (May 1995)
✓	CM	Bourinbaiar AS, Nagorny R., *"Effect of serine protease inhibitor, N-alpha-tosyl-L-lysyl-chloromethyl ketone (TLCK), on cell-mediated and cell-free HIV-1 spread"*, Cell Immunol, 155(l):230-6 (Apr 15, 1994)

EXAMINER	/William Moore/	DATE CONSIDERED	04/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in onformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.M./

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
	APPLICANT Leland SHAPIRO	
	FILING DATE March 3, 2000	GROUP 1646

		OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)
✓	CN	Bratt J, Palmblad J. *Cytokine-induced neutrophil1 5 mediated injury of human endothelial cells. J Immunol* 1997 Jul 15; 159(2):812-8
✓	CO	Brinkmann T, Schafers J, Gurtler L, Kido H, Niwa Y, Katunuma N, Tschesche H., "*Inhibition of tryptase TL2 from human T4+ lymphocytes and inhibition of HIV-1 replication of H9 cells by recombinant aprotinin and bikunin homologues*", J Protein Chem, 16(6):651-60) (Aug 1997)
✓	CP	Bristow CL, Fiscus SA, Flood PM, Arnold RR., *"Inhibition of HIV-1 by modification of a host membrane protease", Int Immunol*, 7(2):239-49 (Feb 1995)
✓	CQ	Bukrinskaia AG, Korneeva MN, Nosik DN, Zhdanov VM., *"Inhibition of HIV reproduction in cultured cells using proteolysis inhibitors"*, Vopr Virusol, 34(1):53-5 (Jan-Feb 1989) English Abstract only at page 55.
✓	CR	Bukrinskaia AG, Kitsak Vla, Moisiadi SA, Arakelov SA. *Suppression of rotavirus SA-II reproduction by protease inhibitors in cell culture.* Vopr Virusol 1987 Jan-Feb;32(1):71-4 English abstract only at page 74.
✓	CS	Carroccio A, Fontana M, Spagnuolo MI, Zuin G, Montalto G, Canani RB, Verghi F, Di Martino D, Bastoni K, Buffardi F, Guarino A., *"Pancreatic dysfunction and its association with fat malabsorption in HIV infected children"*,Gut,43(4):558-63 (Oct 1998)
	CT	Chesnokova NB, Maichuk YF. *Antiproteases in herpetic keratitis.* Metab Pediatr Syst Ophthalmol 1986;9(1):593-6
English Abstract	CU	Chesnokova NB, Kasavina BS, Maichuk luF, Kazachenko MA, Shchipanova Al. *Main proteolytic inhibitors in ocular herpes.* Vopr Med Khim 1981 Sep-Oct;27(5):663-5
	CV	Cilberto et al., 1995, *Cell*, 41:531-540
✓	CW	Cordiali Fei et al., "*Behavior of several 'progression markers' during the HIV-Ab seroconversion period. Comparison with later stages*", J Biol Regul Homeost Agents, 6(2):57-64 (Apr-Jun 1992)
	CX	Cox et al., *"Synergistic combinations and peptides in the inhibition of human immunodeficiency virus"*, Adv Enzyme Regul, 31:85-97 (1991)
	CY	Deam DR, Byron KA, Ratnaike S, Campbell DG, Mulhall BP, Mackay IR., *"Alpha 1-antitrypsin phenotypes in homosexual men"*, Pathology, 21(2):91-2 (Apr 1989)
✓	CZ	Decroly E, Wouters S, Di Bello C, Lazure C, Ruysschaert JM, Seidah NG., "*Identification of the paired basic convertases implicated in HIV gp 160 processing based on in vitro assays and expression in CD4(+) cell lines*", J Biol Chem, 271(48):30442-50 (Nov 1996)
	CAA	Dery, 0. and Bunnett, *N.W. Biochem Soc Trans 1999*, 2 7,246-254

EXAMINER	/William Moore/	DATE CONSIDERED	04/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.M./

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
	APPLICANT Leland SHAPIRO	
	FILING DATE March 3, 2000	GROUP 1646

		OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)
	CAB	Dery, 0. et al. *Am J Physiol 1998, 2 74,* C 1429-C 1452
	CAC	DiIanni CL, Drier DA, Deckman IC, McCann PJ 3d, Liu F, Roizinan B, Colonno RJ, Cordingley MG. Identification of the herpes simplex virus-I protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products. Biol Chem 1993 Jan 25;268(3):2048-51
✓	CAD	Dilanni CL, Stevens JT, Bolgar M, O'Boyle DR 2nd, Weinheimer SP, Colonno RJ. Identification of the serine residue at the active site of the herpes simplex virus type 1 protease. J Biol Chem 1994 Apr 29;269(17):12672-6
	CAE	Ding, A. et al., in J. *Immunol.* 1990, 145, 940
✓	CAF	Estaquier J, Tanaka M, Suda T, Nagata S, Golstein P, Ameisen JC. Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Blood 1996 Jun 15;87(12):4959-66
	CAG	Flaitz CM, Hicks MJ. "Molecular piracy: the viral link to carcinogenesis." *Oral Oncol* 1998 Nov;34(6):448-53
✓	CAH	Franzusoff A, Volpe AM, Josse D, Pichuantes S, Wolf JR., "*Biochemical and genetic definition of the cellular protease required for HIV-1 gp160 processing*", J Biol Chem 1995 Feb 17;270(7):3154-9
✓	CAI	Glozman VN, *"Immunologic foundation of enzyme therapy of patients with orchiepididymitis"*, Antibiot Khimioter, 35(7):50-52 (Jul 1990) English abstract @ page 52.
✓	CAJ	Glynn JM, McElligott DL, Mosier DE. Apoptosis induced by HIV 5 infection in H9 T cells is blocked by ICE-family protease inhibition but not by a Fas(CD95) antagonist. J Immunol 1996 Oct 1;157(7):2754-2758
	CAK	Goureau, 0. et al., in *Proc. Natl. Acad. Sci. U.S.A.* 1993, 90, 4276
✓	CAL	Griffin, William C. , "Calculation of HLB Values of Non-Ionic Sufactants", [H. L. B. - The Hydrophilic-Lipophilic Balance], J. Soc. Cos. Met. Chem., Vol. 5, p. 249 (1954)
✓	CAM	Gu M, Rappaport J, Leppla SH., *"Furin is important but not essential for the proteolytic maturation of gp160 of HIV-1"*, FEBS Lett, 22;365(1):95-7 (May 10, 1995)
✓	CAN	Hallenberger S, Bosch V, Angliker H, Shaw E, Klenk HD, Garten W., "*Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160*", Nature, 26;360(6402):358-61(Nov 26, 1992)
✓	CAO	Harvima et al., "*Separation and partial characterization of proteinases with substrate specificity for basic amino acids from human MOLT-4 T lymphocytes: identification of those inhibited by variable-loop-V3 peptides of HIV-1 (human immunodeficiency virus-1) envelope glycoprotein*", Biochem J, 292 (Pt 3):711-8 (1993)
	CAP	Heck, D. E. et al., in *J. Biol. Chem.* 1990, 267, 21277

EXAMINER	/William Moore/	DATE CONSIDERED	04/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.M./

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
	APPLICANT Leland SHAPIRO	
	FILING DATE March 3, 2000	GROUP 1646

		OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)
	CAQ	Holwerda BC. Herpesvirus proteases: targets for novel antiviral drugs. Antiviral Res 1997 Jun;35(1):1-21
	CAR	Inocencio et al., *"Endoprotease activities other than furin and PACE4 with a role in processing of HIV-I gp160 glycoproteins in CHO-K1 cells"*, J Biol Chem, 272(2):1344-8 (1997)
✓	CAS	Kamoshita K, Shiota M, Sasaki M, Koga Y, Okumura Y, Kido H., *"Calcium requirement and inhibitor spectrum for intracellular HIV type 1 gp160 processing in cultured HeLa cells and CD4+ lymphocytes: similarity to those of viral envelope glycoprotein maturase"*, J Biochem, Jun;117(6):1244-53 (Tokyo Jun 1995)
✓	CAT	Kennedy S, Davis C, Abrams WR, Billings PC, Nagashunmugam T, Friedman H, Malamud D., *"Submandibular salivary proteases: lack of a role in anti-HIV activity"*, *J Dent Res*, 77(7):1515-9 (Jul 1998)
✓	CAU	Kido H, Fukutomi A, Katunuma N., *"A novel membrane-bound serine esterase in human T4+ lymphocytes immunologically reactive with antibody inhibiting syncytia induced by HIV-1. Purification and characterization"*, J Biol Chem., 15:265 (35):21979-85 (Dec 1990)
	CAV	Kido H, Niwa Y, Beppu Y, Towatari T. *Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus. Adv Enzyme Regul* 1996;36:325-47
	CA W	Kirkeboen, K.A. and Strand, O.A. in *Acta Anaesthesiol Scand 1999, 43,* 275
✓	CAX	Koito A, Hattori T, Murakami T, Matsushita S, Maeda Y, Yamamoto T, Takatsuki K., *"A neutralizing epitope of human immunodeficiency virus type 1 has homologous amino acid sequences with the active site of interalpha-trypsin inhibitor"*, Int Immunol, 1(6):613-8 (1989)
	CAY	Langer, R. *Nature* 1998, *392,* ~~5~~ pp. 5-10
✓	CAZ	Lima AA, Silva TM, Gifoni AM, Barrett I-J, McAuliffe IT, Bao Y, Fox JW, Fedorko DP, Guerrant RL., *"Mucosal injury and disruption of intestinal barrier function in HIV-infected individuals with and without diarrhea and cryptosporidiosis in northeast Brazil"*, *Am J Gastroenterol*, 92(10):1861-6 (Oct 1997)

EXAMINER	DATE CONSIDERED
/William Moore/	04/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.M./

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
	APPLICANT Leland SHAPIRO	
	FILING DATE March 3, 2000	GROUP 1646

		OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)
✓	CBA	Lomas DA, Elliott PR, Carrell RW. *Commercial plasma alphal-antitrypsin (Prolastin) contains a conformationally inactive, latent component.* Eur Respir J 1997 Mar;10(3):672-5
	CBB	Lowenstein, C. J. and Snyder, S.H. in *Cell* 1992, 70, 705-707
	CBC	Lowenstein C. J. et al. *in Proc. Natl. Acad. Sci. USA*, 1993, 90, 9730 – 9734.
	CBD	McCall, T.B. et al., in *Biochem. Biophys. Res. Commun.* 1992,186, 680 – 685.
✓	CBE	McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM, *"Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro"*, J Clin Invest, 96(1):456-64 (Jul 1995)
✓	CBF	Meki AR, Mohey El-Dean ZM. *Serum interleukin-lbeta, interleukin-6, nitric oxide and alphal-antitrypsin in scorpion envenomed children.* Toxicon 1998 Dec;36(12):1851-9
✓	CBG	Merrifield, R.B., *"Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide"*, J. Am. Chem. Soc. Vol. 85, ~~p. 2149 (1963)~~ pp. 2149–2154 (1963)
	CBH	Meylan et al., *"HIV infectivity is not augmented by treatment with trypsin, Factor Xa or human mast-cell tryptase"*, AIDS, 6(1):128-30 (1992)
	CBI	Miranda et al., *"Isolation of the human PC6 gene encoding the putative host protease for HIV-1 gp160 processing in CD4+ T lymphocytes"*, Proc Natl Acad Sci U S A, 93(15):7695-7700) (1996)
✓	CBJ	Molle W. et al. in *J Immunol* 1997, 159, 3555 – 3564.
✓	CBK	Moulard M, Achstetter T, Kieny MP, Montagnier L, Bahraoui E, *"Kex2p: a model for cellular endoprotease processing human immunodeficiency virus type 1 envelope glycoprotein precursor"*, Eur J. Biochem, 225(2):565-72 (Oct 15, 1994)
	CBL	Nathan, C. in *FASEB J.* 1992, 6, 3051 – 3064
✓	CBM	Novradovsky A, Brantly ML, Waclawiw MA, Chaudhary PP, Ihara H, Qi L, Tony Eissa N, Barnes PM, Gabriele KM, Ehrmantraut ME, Rogliani P, Moss J. *Endothelial Nitric Oxide Synthase as a Potential Susceptibility Gene in the Pathogenesis of Emphysema in alphal-Antitrypsin Deficiency. Am J Respir Cell Mol Biol* 1999 Mar 1;20(3):441-447
	CBN	Ohnishi et al., *"A furin-defective cell line is able to process correctly the gp160 of human immunodeficiency virus type I"*, J Virol, 68(6):4075-99 (1994)
	CBO	Okumura et al., *"The extracellular processing of HIV- I envelope glycoprotein gp160 by human plasmin"*, FEBS Lett, 442(l):39-42 (1998)
✓	CBP	Ooka T, Hatano Y, Yamamoto M, Ogawa K, Saika S. *Protective effects of human urinary trypsin inhibitor against trypsin-induced relaxation in rat aorta. Crit Care Med* 1996 Nov;24(11):1903-7

EXAMINER	/William Moore/	DATE CONSIDERED	04/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.M./

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
	APPLICANT Leland SHAPIRO	
	FILING DATE March 3, 2000	GROUP 1646

		OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)
	CBQ	Patel R.P., et al. in *Biochim Biophys Acta* 1999,1411,385-400
✓	CBR	Patel T, Gores GJ, Kaufmann SH. *The role of proteases during apoptosis. FASEB J* 1996 Apr;10(5):587-97
	CBS	Pellegrini A, Thomas U, Franchini M, Stockli M, Klauser S, Hunziker P, von Fellenberg R. *Identification of an aprotinin antiviral domain.* FEBS Lett 1994 May 16;344(2-3):261-5
✓	CBT	Pezzilli R, Gullo L, Ricchi E, Costigliola P, Sprovieri G, Pilati G, Fontana G., *"Serum pancreatic enzymes in HIV-seropositive patients"*, Dig Dis Sci, 37(2):286-8 (Feb 1992)
	CBU	Popko B. and Baerwald, K. D. in *Neurochem Res* 1999, *24*, ~~33-1~~ pages 331-338.
✓	CBV	Premack, B. A. and Schall, T. J., *"Chemokine Receptors: Gateways to Inflammation and Infection"*, Nature Medicine, 2, 1174-1178 (1996)
✓	CBW	Pryor WA, Dooley MM, Church DF. *Mechanisms of cigarette smoke toxicity: the inactivation of human alpha-l-proteinase inhibitor by nitric oxide/isoprene mixtures in air.* Chem Biol Interact 1985 Jul;54(2):171-83
	CBX	Punjabi, C. J. et al., in *J. Immunol.* 1992, 149, 2179-2184.
	CBY	Rehman A, Whiteman M, Halliwell B. *Scavenging of hydroxyl radicals but not of peroxynitrite by inhibitors and substrates of nitric oxide syntheses.* Br J Pharmacol 1997 Dec; 122(8):1702-6
	CBZ	*Remington's Pharmaceutical Sciences 1990*, pp. 1519-1675, Gennaro, A. R., ed., Mack Publishing Company, Easton, PA. [Nairn, J.G., Chapter 83]
✓	CCA	Scharpe S, De Meester I, Hendriks D, Vanhoof G, van Sande M, Vriend G, *"Proteases and their inhibitors: today and tomorrow"*, Biochimie, 73(1):121-126 (Jan 1991)
	CCB	Schini et al. in *Circ Res* 1994, 74, 24-32.
	CCC	Schwartz, et al., *"Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1"*, *J Virol*, 72(5):3845-50) (1998)
	CCD	Sharpstone D, Rowbottom A, Nelson M, Gazzard B. *Faecal alpha l antitrypsin as a marker of gastrointestinal disease in HIV antibody positive individuals.* Gut 1996 Feb;38(2):206-10
✓	CCE	Shimizu T, Pommier Y. *DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies.* Exp Cell Res 1996 Aug 1;226(2):292-301
	CCF	Sichko ZhV, Kozlova OL. *Experience in treating a herpetic infection with trypsin* [Article in Russian]. Vrach Delo 1991 Mar;(3):86-9 English Abstract Only

EXAMINER	/William Moore/	DATE CONSIDERED	04/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.M./

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)	ATTY. DOCKET NO. 114232.104	SERIAL NO. 09/518,081
	APPLICANT Leland SHAPIRO	
	FILING DATE March 3, 2000	GROUP 1646

		OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)
	CCG	Smith, M. E. in *Neurochem Res* 1999, *24*, 261
English abstract at page 829.	CCH	Szeghy G, Kenyeres B. *On the therapy of herpes simplex keratitis with heparin and trypsin.* [Article in German] Klin Monatsbl Augenheilkd 1968;153(6):827-30
	CCI	Tang et al.; *"Inactivation of HIV-1 by trypsin and its use in demonstrating specific virus infection of cells"*, J Virol Methods 33(1-2):39-46 (Jun 1991)
	CCJ	Turpin JA, Schaeffer CA, Bu M, Graham L, Buckheit RW Jr, Clanton D, Rice WG, *"Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor", Antiviral Res*, 29(2-3):269-77 (Mar 1996)
	CCK	Van Molle W, Libert C, Fiers W , Brouckaert P. *Alpha I-acid glycoprotein and alpha I-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice.* J Immunol 1997 Oct 1;159(7):3555-64
	CCL	Vollenweider F, Benjannet S, Decroly E, Savaria D, Lazure C, Thomas G, Chretien M, Seidah NG, *"Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp 160 by the mammalian subtilisin/kexin-like convertases"*, Biochem, J;314(Pt2):521-32 (Mar 1996)
	CCM	Wood, E.R. et al. in *Biochem Biophys Res Commun* 1993,191, 767-74
English abstract at page 36.	CCN	Zhirnov OP, Ovcharenko AV, Mel'nikova EE, Gaidamovich Sla, Bukrinskaia AG. *Antiviral activity of proteinase inhibitors in cultured cells infected with alpha-viruses.* Mol Gen Mikrobiol Virusol 1985 Dec;(12):30-6
EXAMINER /William Moore/		DATE CONSIDERED 04/21/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.M./